BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	28.76	29.85	65.22	193.73	232.97
Cash & Short-Term Investments	28.76	29.85	65.22	193.73	232.97
Cash Growth	-3.67%	-54.23%	-66.33%	-16.84%	9.31%
Accounts Receivable	0.23	0.13	0.07	0.25	-
Inventory	0.72	0.68	1.99	1.99	-
Other Current Assets	14.97	6.73	4.86	6.91	3.84
Total Current Assets	44.69	37.39	72.14	202.87	236.81
Net Property, Plant & Equipment	0.23	0.86	1.47	2.06	2.54
Other Long-Term Assets	-	0.09	0.09	0.93	0.09
Total Assets	44.92	38.34	73.7	205.85	239.44
Accounts Payable	14.7	15.99	13.65	10.23	4.68
Accrued Expenses	4.34	5.76	13.16	21.84	11.49
Current Portion of Long-Term Debt	24.93	-	-	-	-
Other Current Liabilities	9.95	0.48	0.45	0.83	0.5
Total Current Liabilities	53.93	22.23	27.27	32.9	16.67
Long-Term Debt	84.66	102.51	100.6	93.05	-
Long-Term Leases	-	0.07	0.44	0.79	1.11
Other Long-Term Liabilities	1.79	6.63	1.91	2.34	-
Total Long-Term Liabilities	86.45	109.21	102.94	96.18	1.11
Total Liabilities	140.38	131.44	130.21	129.08	17.77
Common Stock	0.08	0.05	0.03	0.03	0.03
Additional Paid-in Capital	624.56	557.05	534.06	488.29	467.43
Retained Earnings	-720.09	-650.2	-590.6	-411.55	-245.79
Shareholders' Equity	-95.46	-93.1	-56.51	76.78	221.67
Total Liabilities & Equity	44.92	38.34	73.7	205.85	239.44
Total Debt	109.59	102.57	101.04	93.84	1.11
Net Cash (Debt)	-80.84	-72.72	-35.82	99.89	231.86
Net Cash Growth	-	-	-	-56.92%	9.51%
Net Cash Per Share	-6.62	-28.69	-19.67	57.05	140.67
Book Value	-95.46	-93.1	-56.51	76.78	221.67
Book Value Per Share	-7.82	-36.73	-31.03	43.85	134.48
Tangible Book Value	-95.46	-93.1	-56.51	76.78	221.67
Tangible Book Value Per Share	-7.82	-36.73	-31.03	43.85	134.48

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q